Crohn Disease
"Crohn Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.
Descriptor ID |
D003424
|
MeSH Number(s) |
C06.405.205.731.500 C06.405.469.432.500
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Crohn Disease".
Below are MeSH descriptors whose meaning is more specific than "Crohn Disease".
This graph shows the total number of publications written about "Crohn Disease" by people in this website by year, and whether "Crohn Disease" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1980 | 1 | 1 | 2 | 1981 | 2 | 0 | 2 | 1982 | 3 | 1 | 4 | 1983 | 5 | 0 | 5 | 1984 | 3 | 0 | 3 | 1985 | 3 | 0 | 3 | 1986 | 5 | 1 | 6 | 1987 | 2 | 0 | 2 | 1988 | 4 | 0 | 4 | 1989 | 5 | 0 | 5 | 1990 | 3 | 0 | 3 | 1991 | 7 | 0 | 7 | 1992 | 3 | 0 | 3 | 1993 | 6 | 2 | 8 | 1994 | 0 | 2 | 2 | 1995 | 5 | 1 | 6 | 1996 | 4 | 1 | 5 | 1997 | 4 | 0 | 4 | 1998 | 6 | 1 | 7 | 1999 | 8 | 3 | 11 | 2000 | 15 | 1 | 16 | 2001 | 13 | 1 | 14 | 2002 | 17 | 2 | 19 | 2003 | 13 | 2 | 15 | 2004 | 24 | 1 | 25 | 2005 | 19 | 1 | 20 | 2006 | 13 | 4 | 17 | 2007 | 25 | 4 | 29 | 2008 | 11 | 3 | 14 | 2009 | 12 | 2 | 14 | 2010 | 12 | 1 | 13 | 2011 | 15 | 4 | 19 | 2012 | 14 | 3 | 17 | 2013 | 24 | 3 | 27 | 2014 | 16 | 0 | 16 | 2015 | 10 | 3 | 13 | 2016 | 21 | 3 | 24 | 2017 | 14 | 3 | 17 | 2018 | 23 | 1 | 24 | 2019 | 12 | 5 | 17 | 2020 | 21 | 3 | 24 | 2021 | 22 | 1 | 23 | 2022 | 13 | 0 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Crohn Disease" by people in Profiles.
-
Cohen NA, Micic DM, Sakuraba A. Factors associated with poor compliance amongst hospitalized, predominantly adolescent pediatric Crohn's disease patients. Ann Med. 2022 12; 54(1):886-892.
-
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 06 11; 399(10342):2200-2211.
-
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 05 28; 399(10340):2015-2030.
-
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022 05 28; 399(10340):2031-2046.
-
Taft TH, Quinton S, Jedel S, Simons M, Mutlu EA, Hanauer SB. Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes. Inflamm Bowel Dis. 2022 05 04; 28(5):710-719.
-
Parigi TL, D'Amico F, Abreu MT, Rubin DT, Dignass A, Dotan I, Jairath V, Magro F, Peyrin-Biroulet L, Ghosh S, Danese S. Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. Lancet Gastroenterol Hepatol. 2022 05; 7(5):390-391.
-
Ananthakrishnan AN, Kaplan GG, Bernstein CN, Burke KE, Lochhead PJ, Sasson AN, Agrawal M, Tiong JHT, Steinberg J, Kruis W, Steinwurz F, Ahuja V, Ng SC, Rubin DT, Colombel JF, Gearry R. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. Lancet Gastroenterol Hepatol. 2022 Jul; 7(7):666-678.
-
Friedberg S, Rubin DT. Intestinal Cancer and Dysplasia in Crohn's Disease. Gastroenterol Clin North Am. 2022 Jun; 51(2):369-379.
-
Cohen NA, Pekow J. Editorial: time to modify practice and use the modified Rutgeert's score. Aliment Pharmacol Ther. 2022 03; 55(6):754-755.
-
Sandborn WJ, D'Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. 2022 05; 162(6):1650-1664.e8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|